131 related articles for article (PubMed ID: 19274614)
21. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
22. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
[TBL] [Abstract][Full Text] [Related]
23. Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
25. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
Zinzani PL; Magagnoli M; Bendandi M; Orcioni GF; Gherlinzoni F; Albertini P; Pileri SA; Tura S
Ann Oncol; 1998 Dec; 9(12):1351-3. PubMed ID: 9932168
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
[TBL] [Abstract][Full Text] [Related]
27. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
Martoni A; Di Fabio F; Guaraldi M; Piana E; Ramini R; Lelli G; Palomba G; Artioli F; Bandieri E; Robustelli Della Cuna G; Preti P
Am J Clin Oncol; 2001 Dec; 24(6):614-7. PubMed ID: 11801766
[TBL] [Abstract][Full Text] [Related]
28. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
[TBL] [Abstract][Full Text] [Related]
29. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Santoro A; Bredenfeld H; Devizzi L; Tesch H; Bonfante V; Viviani S; Fiedler F; Parra HS; Benoehr C; Pacini M; Bonadonna G; Diehl V
J Clin Oncol; 2000 Jul; 18(13):2615-9. PubMed ID: 10893294
[TBL] [Abstract][Full Text] [Related]
31. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Venkatesh H; Di Bella N; Flynn TP; Vellek MJ; Boehm KA; Asmar L
Clin Lymphoma; 2004 Sep; 5(2):110-5. PubMed ID: 15453926
[TBL] [Abstract][Full Text] [Related]
32. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Ridwelski K; Fahlke J; Kuhn R; Hribaschek A; Kettner E; Greiner C; Florschuetz A; Manger T; Wilhelm G; Klein H; Hahnfeld S; Lippert H; Meyer F
Eur J Surg Oncol; 2006 Apr; 32(3):297-302. PubMed ID: 16414235
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
Ahn HK; Kim SJ; Hwang DW; Ko YH; Tang T; Lim ST; Kim WS
Invest New Drugs; 2013 Apr; 31(2):469-72. PubMed ID: 23108598
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Ferraresi V; Ciccarese M; Cercato MC; Nuzzo C; Zeuli M; Di Filippo F; Giannarelli D; Cognetti F
Cancer Chemother Pharmacol; 2008 Dec; 63(1):149-55. PubMed ID: 18351342
[TBL] [Abstract][Full Text] [Related]
35. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma.
Bernell P; Ohm L
Br J Haematol; 1998 Apr; 101(1):203-4. PubMed ID: 9576202
[TBL] [Abstract][Full Text] [Related]
36. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ
Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine for relapsed or resistant lymphoma.
Savage DG; Rule SA; Tighe M; Garrett TJ; Oster MW; Lee RT; Ruiz J; Heitjan D; Keohan ML; Flamm M; Johnson SA
Ann Oncol; 2000 May; 11(5):595-7. PubMed ID: 10907954
[TBL] [Abstract][Full Text] [Related]
38. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
[TBL] [Abstract][Full Text] [Related]
39. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
Morant R; Bernhard J; Maibach R; Borner M; Fey MF; Thürlimann B; Jacky E; Trinkler F; Bauer J; Zulian G; Hanselmann S; Hürny C; Hering F
Ann Oncol; 2000 Feb; 11(2):183-8. PubMed ID: 10761753
[TBL] [Abstract][Full Text] [Related]
40. When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer.
Nacci A; Calvani N; Rizzo P; Fedele P; Orlando L; Schiavone P; Cinefra M; Marino A; Sponziello F; D'Amico M; Cinieri S
Med Oncol; 2013 Mar; 30(1):370. PubMed ID: 23322519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
